Literature DB >> 9308373

Charting WHO--goals for licit and illicit drugs for the year 2000: are we 'on track'?

B Fischer1, P Kendall, J Rehm, R Room.   

Abstract

Both on a global and a regional basis, the World Health Organization (WHO) has set prominent goals for the turn of the millennium on the reduction of harms associated with licit and illicit drugs. Gauging what the world and its different regions are doing with respect to these specific public health goals is hindered by a conceptual problem: there is no clear concept and consistent way of defining or measuring 'harm' related to drugs, licit or illicit. In many instances, 'harm' is equated with substance use prevalence. Often, especially outside the developed world, basic harm data is not even available. Globally, a conceptually clear and consistently applied scheme of harm measurement related to licit and illicit drugs is needed, acknowledging the fact that drug-related harms occur at different individual and social levels as well as over different periods of time. Harms must also be recognized as an outcome of interactions between the substance user, the drug itself, and the physical and social environment. Looking at available macro-indicators of harm, it must be concluded with, we do not seem to be 'on track' globally in reducing harms related to drugs in accordance with the WHO goals. For alcohol and tobacco, trends for increased harm are just starting to show in the developing world, and will worsen over the next couple of decades. For illicit drugs, failing drug control policies have result in dramatically negative developments for public health, especially with respect to HIV infections and drug-related deaths, in the developed as well as developing world.

Entities:  

Mesh:

Year:  1997        PMID: 9308373     DOI: 10.1038/sj.ph.1900391

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   2.427


  10 in total

1.  Large decline in injecting drug use in Amsterdam, 1986-1998: explanatory mechanisms and determinants of injecting transitions.

Authors:  E J van Ameijden; R A Coutinho
Journal:  J Epidemiol Community Health       Date:  2001-05       Impact factor: 3.710

2.  Social costs of untreated opioid dependence.

Authors:  R Wall; J Rehm; B Fischer; B Brands; L Gliksman; J Stewart; W Medved; J Blake
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

3.  Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time.

Authors:  B Fischer; J Rehm; T Blitz-Miller
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

4.  Substance abuse at the turn of the millennium.

Authors:  P R Kendall; J Hoey
Journal:  CMAJ       Date:  1999-05-18       Impact factor: 8.262

Review 5.  Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS.

Authors:  L Degenhardt; W Hall; M Warner-Smith
Journal:  Sex Transm Infect       Date:  2006-06       Impact factor: 3.519

Review 6.  Alcohol use and sexual risk behaviors and outcomes in China: a literature review.

Authors:  Qing Li; Xiaoming Li; Bonita Stanton
Journal:  AIDS Behav       Date:  2010-12

7.  Drug, sex and age differentials in the use of Australian publicly funded treatment services.

Authors:  Jane Anne Fischer; Alexandra Marie Clavarino; Jackob Moses Najman
Journal:  Subst Abuse       Date:  2012-03-07

8.  Comparative risk assessment of alcohol, tobacco, cannabis and other illicit drugs using the margin of exposure approach.

Authors:  Dirk W Lachenmeier; Jürgen Rehm
Journal:  Sci Rep       Date:  2015-01-30       Impact factor: 4.379

9.  An ethical analysis of UK drug policy as an example of a criminal justice approach to drugs: a commentary on the short film Putting UK Drug Policy into Focus.

Authors:  Adam Holland
Journal:  Harm Reduct J       Date:  2020-12-09

10.  Personalized risk assessment of drug-related harm is associated with health outcomes.

Authors:  Andrea A Jones; Fidel Vila-Rodriguez; William J Panenka; Olga Leonova; Verena Strehlau; Donna J Lang; Allen E Thornton; Hubert Wong; Alasdair M Barr; Ric M Procyshyn; Geoffrey N Smith; Tari Buchanan; Mel Krajden; Michael Krausz; Julio S Montaner; G William Macewan; David J Nutt; William G Honer
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.